Private Equity

A $2.4B semiconductor deal seems distant from medicine, but it's forging the AI hardware backbone for the next generation of precision health.

Bregal Milestone's majority investment in Beyond Now is more than a deal; it’s a bet on how Agentic AI will rewire complex digital supply chains.

With a massive lodge expansion and an all-inclusive dining plan, the cruise line is making a strategic play to dominate the lucrative Alaska land-tour market.

The 2025 proxy season saw record director support as investors prioritized financials, yet dissent over executive pay signals a new battleground.

Balyasny Asset Management's complex derivative stake in JTC plc reveals the hidden strategies shaping a major takeover and the capital flows funding innovation.

With a new patent, this biotech targets the massive orthopedics market. But can its novel fibroblast therapy overcome steep financial and clinical hurdles?

A crypto fund's nomination for a top award signals a new era for family offices seeking managed risk and high returns in the volatile digital asset market.

Copper Quest diversifies from copper, acquiring a high-grade gold mine and adding 150+ years of mining expertise to its board and advisory team.

Beyond philanthropy, KinderCare's alumni scholarship is a strategic investment in its brand, building a human capital pipeline from the ground up.

Ontario's new FAST program speeds access to cancer drugs like Scemblix, challenging Canada's slow reimbursement system. Is this a new national blueprint?

A routine filing reveals Marathon Asset Management's 3.68% stake in John Wood Group. What does this calculated play signal for the firm's takeover?

UNFI unveils an ambitious strategy to hit $800M in EBITDA by 2028, shifting focus from pure sales to deep operational and digital transformation.

Applegate unites with 11 mission-driven brands in a campaign that redefines partnerships, weaving CSR and consumer engagement into a powerful new strategy.

A Canadian youth sports leader's entry into India reveals a blueprint for AI-driven physical literacy and a new paradigm for children's healthcare.

Providence Care's new CEO is a former therapist. Can his clinical insight solve market challenges and deliver on a private equity growth plan?

Capital Power unveils a $3B deal with Apollo to buy U.S. gas plants while securing a major deal to power Alberta's AI boom, a bold dual strategy.

A novel drug for heart failure shows promising safety and efficacy data, potentially disrupting a multi-billion dollar market and validating a key investor's strategy.

Bill Ackman's fund is buying back its own shares at a deep discount. We explore the innovative financial strategy and its impact on shareholder value.

Denali Therapeutics raises $200M to advance its brain-penetrating drugs, betting big on its pipeline despite short-term market jitters.

Following stellar clinical data, Terns Pharmaceuticals' upsized $650M offering signals massive investor confidence and funds its push to disrupt the CML market.